TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

Table 3 Cox univariate models for time to progression and overall survival ^a

			Time to progression				Overall survival
Risk factor	n	HR	95% CI		P	HR	95% CI		P
TIMP-1 (positive vs. negative)	264	0.90	(0.61-	1.31)	0.57	0.742	(0.55-	1.01)	0.06

^aModels not stratified.
Abbreviations: CI Confidence interval, HR Hazard ratio, TIMP-1 Tissue inhibitor of metalloproteinases-1.

ISSN: 1471-2407